menu

Loading...

MRNA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

54.930

Open

52.430

VWAP

52.75

Vol

9.38M

Mkt Cap

21.16B

Low

50.480

Amount

494.82M

EV/EBITDA(TTM)

--

Total Shares

394.94M

EV

15.99B

EV/OCF(TTM)

--

P/S(TTM)

10.72

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Show More

Events Timeline

(ET)

2026-02-27

07:20:00

Moderna's mCOMBRIAX Vaccine Receives Positive Opinion from EU

2026-02-27

07:20:00

Moderna's mCOMBRIAX Vaccine Receives Positive Opinion from EMA

2026-02-23 (ET)

2026-02-23

10:20:00

Moderna Shares Rise 5.92% to $52.82

2026-02-23

10:00:00

Texas Pacific Land Trust Rises $37.50 to $537.38

2026-02-18 (ET)

2026-02-18

16:40:00

Major Averages Rise Following Fed Meeting Minutes

2026-02-18

12:10:00

Major Averages Broadly Higher, Tech Stocks Perform Strongly

2026-02-18

11:10:00

RBC: FDA Sets Moderna Flu Vaccine Price Target at $30

News

NASDAQ.COM

21:04 PMNASDAQ.COM

Flex LNG and Moderna Options Show High Trading Volume

Barron's

18:13 PMBarron's

Three Key Sectors to Monitor While the S&P 500 Moves Sideways

seekingalpha

02-27seekingalpha

EMA Recommends Moderna's Combined COVID-19 and Influenza Vaccine

moomoo

MODERNA EXPECTS BROADER ACCESS TO MCOMBRIAX IN THE EU BY 2027

moomoo

Novavax Executive Expresses Optimism About Moderna's Advancements in Flu Vaccine Development

CNBC

Salesforce Reports Strong Q4 Results, Stock Drops Amid AI Concerns

20 Analyst Rating

Wall Street analysts forecast MRNA stock price to rise

1 Buy

16 Hold

3 Sell

Hold

Current: 0.000

Low

17.00

Averages

32.47

High

63.00

Current: 0.000

Low

17.00

Averages

32.47

High

63.00

Piper Sandler

NULL -> Overweight

upgrade

$63 -> $69

AI Analysis

2026-02-23

Reason

Piper Sandler

Price Target

$63 -> $69

AI Analysis

2026-02-23

upgrade

NULL -> Overweight

Reason

Piper Sandler raised the firm's price target on Moderna to $69 from $63 and keeps an Overweight rating on the shares. The firm forecasts total product sales of $2.07B in 2026 driven by growth of next-generation COVID vaccine mNEXSPIKE. Following a Type A meeting, the FDA will review the BLA for seasonal flu vaccine mRNA-1010 for full approval in adults aged 50-64 years and accelerated approval for adults 65-plus years setting an August 5th PDUFA date.

BofA

Alex Stranahan

Underperform

maintain

$27 -> $31

2026-02-19

Reason

BofA

Alex Stranahan

Price Target

$27 -> $31

2026-02-19

maintain

Underperform

Reason

BofA analyst Alex Stranahan raised the firm's price target on Moderna to $31 from $27 and keeps an Underperform rating on the shares after the company announced that the FDA had reversed course and accepted for review the BLA filing for mRNA-1010 with a slightly altered regulatory path and PDUFA date of August 5. While the firm returns its flu build in the U.S. to its model, with assumptions of 7% peak penetration and 70% odds of success, it reiterates an Underperform rating as it still sees the path ahead for mRNA-1010 as unclear.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRNA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is -3.67, compared to its 5-year average forward P/E of -2.07. For a more detailed relative valuation and DCF analysis to assess Moderna Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.07

Current PE

-3.67

Overvalued PE

11.38

Undervalued PE

-15.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.22

Current EV/EBITDA

-2.40

Overvalued EV/EBITDA

7.57

Undervalued EV/EBITDA

-12.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

6.31

Current PS

6.29

Overvalued PS

9.04

Undervalued PS

3.58

Financials

AI Analysis

Annual

Quarterly

Whales Holding MRNA

Two Sigma Investments, LP

Lingotto Investment Management LLP

Theleme Partners LLP

Aquatic Capital Management LLC

Tang Capital Management, LLC

Sessa Capital IM, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Moderna Inc (MRNA) stock price today?

The current price of MRNA is 52.845 USD — it has decreased -1.35

What is Moderna Inc (MRNA)'s business?

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

What is the price predicton of MRNA Stock?

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is32.47 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Moderna Inc (MRNA)'s revenue for the last quarter?

Moderna Inc revenue for the last quarter amounts to 678.00M USD, decreased -29.81

What is Moderna Inc (MRNA)'s earnings per share (EPS) for the last quarter?

Moderna Inc. EPS for the last quarter amounts to -2.11 USD, decreased -26.99

How many employees does Moderna Inc (MRNA). have?

Moderna Inc (MRNA) has 4700 emplpoyees as of March 02 2026.

What is Moderna Inc (MRNA) market cap?

Today MRNA has the market capitalization of 21.16B USD.